(Q38072056)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293858%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

review article

1 reference

title

Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293858%20AND%20SRC:MED&resulttype=core&format=json

eradication of infectious diseases

21 February 2020

main subject

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293858%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Weizao Chen

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293858%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Dimiter S Dimitrov

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293858%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

language of work or name

English

0 references

publication date

7 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293858%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

21 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293858%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293858%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293858%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

657-671

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293858%20AND%20SRC:MED&resulttype=core&format=json

HIV reservoirs and strategies for eradication

21 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

HIV reservoirs: pathogenesis and obstacles to viral eradication and cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Towards an HIV cure: a global scientific strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

HIV reservoirs and the possibility of a cure for HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

An update in the development of HIV entry inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Therapeutic antibodies: current state and future trends--is a paradigm change coming soon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

21 January 2018

Therapeutic proteins.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Candidate antibody-based therapeutics against HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Recombinant hepatitis B vaccine: a review of its immunogenicity and protective efficacy against hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Comparison of immune responses against foot-and-mouth disease virus induced by fusion proteins using the swine IgG heavy chain constant region or beta-galactosidase as a carrier of immunogenic epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Generation of Human Monoclonal Antibodies against HIV-1 Proteins; Electrofusion and Epstein-Barr Virus Transformation for Peripheral Blood Lymphocyte Immortalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Increasing the potency and breadth of an HIV antibody by using structure-based rational design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Broad neutralization coverage of HIV by multiple highly potent antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Antibody-based protection against HIV infection by vectored immunoprophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Elicitation of structure-specific antibodies by epitope scaffolds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Scaffolding to build a rational vaccine design strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Role of HIV membrane in neutralization by two broadly neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimetic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Antigenic conservation and immunogenicity of the HIV coreceptor binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Structural definition of a conserved neutralization epitope on HIV-1 gp120

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Fusion proteins of HIV-1 envelope glycoprotein gp120 with CD4-induced antibodies showed enhanced binding to CD4 and CD4 binding site antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Structural mechanism of trimeric HIV-1 envelope glycoprotein activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Cross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope Glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Rational modifications of HIV-1 envelope glycoproteins for immunogen design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

HIV-1 virus-like particles produced by stably transfected Drosophila S2 cells: a desirable vaccine component

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Anti-HIV B Cell lines as candidate vaccine biosensors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and design of vaccine immunogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

P04-07. Guiding the immune system through complex maturation pathways: a novel multi-immunogen approach for elicitation of broadly neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Therapeutic antibodies, vaccines and antibodyomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Molecular Understanding of HIV-1 Latency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Long-term cultures of HTLV-III--infected T cells: a model of cytopathology of T-cell depletion in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

An inducible transcription factor activates expression of human immunodeficiency virus in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

CpG oligodeoxynucleotides activate HIV replication in latently infected human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Prostratin as a new therapeutic agent targeting HIV viral reservoirs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

High-throughput screening uncovers a compound that activates latent HIV-1 and acts cooperatively with a histone deacetylase (HDAC) inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Topology of the C-terminal tail of HIV-1 gp41: differential exposure of the Kennedy epitope on cell and viral membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Therapeutic antibodies against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Optimizing denileukin diftitox (Ontak) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.761969

Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Monoclonal antibody-based candidate therapeutics against HIV type 1.

1 reference

12 December 2020

Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia

1 reference

12 December 2020

Molecular structures of trimeric HIV-1 Env in complex with small antibody derivatives.

1 reference

12 December 2020

Quantitation of human immunodeficiency virus type 1 infection kinetics

1 reference

12 December 2020

Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

1 reference

12 December 2020

Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy

1 reference

12 December 2020

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.

1 reference

12 December 2020

10.1517/14712598.2013.761969

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293858%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293858%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

PubMed publication ID

23293858

1 reference